Transdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
AssigneeWhite Mountain Pharma, Inc.
InventorsHillary D. White, Robert Gyurik
Life of this patent
Estimating the term…
Abstract
Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones.
Claims17
A method of alleviating the symptoms of fibromyalgia in a human female patient suffering from deficient serum testosterone levels, comprising administering daily to the patient suffering from deficient serum testosterone levels, a safe and effective amount of a transdermal testosterone gel composition which is both effective for alleviating the female patient's symptoms of fibromyalgia and for consistently raising the female patient's serum testosterone levels only within limits approximating the reference range for normal premenopausal women, wherein the composition contains a daily unit dose of testosterone and is formulated to provide steady state total testosterone serum levels without raising free testosterone serum levels or twenty-four hour free testosterone AUC above the levels required for both therapeutic efficacy and safety.
A method of alleviating the symptoms of fibromyalgia in a human female patient suffering from deficient serum testosterone levels, comprising administering daily to the female patient a transdermal testosterone gel composition that is safe and effective for raising a human female patient's serum testosterone levels only within limits approximating the reference range for normal premenopausal women, wherein steady state concentrations, defined by mean concentrations through an approximately 24 hour sampling period, established after Day 1 and are within limits approximating the reference range for normal premenopausal women.
A method of increasing serum testosterone levels in a human female patient deficient in serum testosterone levels, comprising administering daily to the female patient a transdermal testosterone gel composition that is safe and effective for raising a human female patient's serum testosterone levels only within limits approximating the reference range for normal premenopausal women, wherein a mean serum concentration of total testosterone 24 hours after application of a first dose of the composition on Day 1 is higher than a mean serum concentration for time zero on Day 1 and, on average, is sustained throughout an approximately 28 day period and remains within limits approximating the reference range for normal premenopausal women.
A method of increasing serum testosterone levels in a human female patient deficient in serum testosterone levels comprising administering daily to the female patient a transdermal testosterone gel composition that is safe and effective for raising a human female patient's serum testosterone levels only within limits approximating the reference range for normal premenopausal women, wherein a mean serum concentration of total testosterone 24 hours after application of a first dose of the composition on Day 1 is higher than a mean serum concentration for time zero on Day 1 and steady state concentrations, defined by mean concentrations throughout an approximately 24 hour sampling period, on average, are established after Day 1 and remain within limits approximating the reference range for normal premenopausal women.
A method of increasing serum testosterone levels in a human female patient deficient in serum testosterone levels comprising administering daily to the female patient a transdermal testosterone gel composition that is safe and effective for raising a human female patient's serum testosterone levels only within limits approximating the reference range for normal premenopausal women, wherein steady state concentrations, defined by mean concentrations throughout the day for an approximately 24 hour sampling period, on average, are established after Day 1 and remain within limits approximating the reference range for normal premenopausal women.
Dependencies are inferred from the claim text.